Avory & Company LLC Sells 12,926 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Avory & Company LLC lessened its stake in Omnicell, Inc. (NASDAQ:OMCL) by 5.1% during the fourth quarter, Holdings Channel reports. The firm owned 241,206 shares of the company’s stock after selling 12,926 shares during the period. Omnicell makes up about 6.0% of Avory & Company LLC’s holdings, making the stock its 6th biggest holding. Avory & Company LLC’s holdings in Omnicell were worth $10,738,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in OMCL. Pier Capital LLC acquired a new position in shares of Omnicell during the 3rd quarter valued at $5,859,000. Royce & Associates LP acquired a new position in shares of Omnicell during the 3rd quarter valued at $811,000. Geode Capital Management LLC lifted its holdings in shares of Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after acquiring an additional 2,877 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Omnicell during the 3rd quarter valued at $753,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after acquiring an additional 259,463 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Performance

Omnicell stock opened at $37.82 on Thursday. The firm’s fifty day moving average price is $42.03 and its 200 day moving average price is $43.72. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of 140.08, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, research analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Insider Transactions at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.64% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on OMCL shares. JPMorgan Chase & Co. lifted their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Bank of America reduced their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Benchmark reaffirmed a “buy” rating and set a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Finally, StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $52.33.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.